



Ventripoint Diagnostics Appoints Thomas Brown as Director of Congenital Heart Defect Program

Toronto, Ontario, August 18, 2025 – Ventripoint Diagnostics Ltd. (“**Ventripoint**” or the “**Corporation**”, TSXV:VPT; OTC:VPTDF) a leader in AI-powered heart analysis solutions, is pleased to announce the appointment of **Thomas Brown**, former Vice President of North American Sales at Intelligent Ultrasound, as **Director of the Congenital Heart Defect (CHD) Program**.

Mr. Brown brings more than 20 years of leadership experience in global medical imaging sales, commercialization, and market expansion. At Intelligent Ultrasound, he drove significant international growth, launching AI-powered imaging solutions into both clinical and training markets.

This appointment is a strategic move to accelerate Ventripoint’s market leadership in the congenital heart defect segment - one of the largest and fastest-growing areas in pediatric cardiology - with the potential to expand adoption of VMS+™ into related high-value markets such as cardio-oncology, pulmonary hypertension, heart failure, and valve disease.

“Thomas’s expertise in scaling innovative imaging solutions will be a catalyst for growth in our CHD program and beyond,” said Hugh MacNaught, President & CEO of Ventripoint Diagnostics. “This is a key step in executing our multi-segment growth strategy.”

Ventripoint’s VMS+™ technology enables accurate, MRI-comparable cardiac volumetric analysis using standard 2D cardiac ultrasound - dramatically reducing costs, eliminating wait times, and expanding access for clinicians and patients.

Mr. Brown’s career spans over 20 years in healthcare technology sales and market development, with a focus on introducing innovative imaging solutions into clinical practice. At Intelligent Ultrasound, he was responsible for significant revenue growth, international market expansion, and the launch of cutting-edge AI products into the healthcare ecosystem.

“I’m excited to join Ventripoint at such a pivotal time in the company’s growth,” said Mr. Brown. “The potential of Ventripoint’s AI-powered solutions to transform how congenital heart defects are diagnosed and monitored is tremendous, and I look forward to working with the team to bring this vision to life.”

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary

knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Group/Documents/Ventripoint/Shares for Interest re Debentures/Interest re January 17, 2025 Debentures/Press Release/ PR re May 2024, Sept 2024, Dec 2024 shares for interest v1.docx